
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 30 years ago
Goals and Objectivesover 30 years ago
Introductionover 30 years ago
Switch Therapy: Development, Implementation, and Economics





